Welcome to our dedicated page for Clearside Biomed SEC filings (Ticker: CLSD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode a biotech filing packed with clinical data and regulatory jargon is tough—especially when Clearside Biomedical’s future hinges on each trial update and capital raise. Our SEC Filings hub tackles that problem head-on. Whether you’re scanning for Clearside Biomedical insider trading Form 4 transactions or need the fine print on a licensing deal buried in an 8-K material events explained report, Stock Titan’s AI spots what moves the stock and summarizes it in plain English.
Every document—from the Clearside Biomedical annual report 10-K simplified to the latest quarterly earnings report 10-Q filing—lands here seconds after it appears on EDGAR. Our platform automatically extracts R&D spend, cash runway, and clinical milestone disclosures, so you can focus on the implications, not the page count. Curious about executive sentiment? Get Clearside Biomedical executive stock transactions Form 4 with real-time alerts and trend graphs. Want a quick readout of last night’s financing? Check the shelf registration S-3 summary our AI generated while you slept.
Use cases professionals rely on daily:
- Compare trial expense trends quarter-over-quarter with our Clearside Biomedical earnings report filing analysis.
- Receive push notifications for Clearside Biomedical Form 4 insider transactions real-time before the market digests them.
- Skip to key risk-factor changes using “understanding Clearside Biomedical SEC documents with AI.”
- Review board pay details pulled from the latest Clearside Biomedical proxy statement executive compensation.
No more sifting through PDFs—our expert, AI-powered summaries turn hundreds of pages into actionable insights, updated the moment Clearside files.
FAQ
What is the current stock price of Clearside Biomed (CLSD)?
The current stock price of Clearside Biomed (CLSD) is $0.409 as of July 18, 2025.
What is the market cap of Clearside Biomed (CLSD)?
The market cap of Clearside Biomed (CLSD) is approximately 68.0M.
What is Clearside Biomedical's primary focus?
Clearside Biomedical focuses on developing therapies for blinding eye diseases using its proprietary suprachoroidal space (SCS) injection platform.
What is the SCS Microinjector?
The SCS Microinjector is a minimally invasive device that enables targeted, in-office delivery of therapies to the back of the eye via the suprachoroidal space.
How does Clearside generate revenue?
Clearside generates revenue through strategic partnerships, licensing agreements, and potentially the commercialization of its therapies.
What diseases does Clearside target?
Clearside targets sight-threatening conditions such as macular edema, diabetic retinopathy, and uveitis.
What makes Clearside's technology unique?
Clearside's SCS injection platform offers targeted, compartmentalized drug delivery with enhanced precision, safety, and repeatability compared to traditional methods.
What are the challenges Clearside Biomedical faces?
Clearside faces challenges such as regulatory approvals, clinical trial success, and achieving market adoption for its novel technology.
Who are Clearside Biomedical's competitors?
Clearside competes with both established pharmaceutical companies and emerging biotech firms in the ophthalmic pharmaceutical market.
What is the potential market for Clearside's therapies?
Clearside operates in the growing ophthalmology market, driven by the aging population and increasing prevalence of chronic eye diseases.
What is the significance of the suprachoroidal space in Clearside's approach?
The suprachoroidal space allows for targeted and compartmentalized drug delivery, improving treatment efficacy and minimizing systemic exposure.
What opportunities exist for Clearside Biomedical?
Clearside has opportunities to expand through strategic partnerships, advancing its pipeline, and addressing unmet medical needs in ophthalmology.